RESUMO
OBJECTIVE: To evaluate the therapeutic effects and safety of the XIA's No.1 Sleeping Prescription for the treatment of insomnia of the deficiency type. METHODS: 120 cases conformed to the diagnostic criteria of the Chinese Classification of Mental Disorders-Version 3 (CCMD-3) and were diagnosed as having insomnia of the deficiency type were divided randomly into a treatment group and a control group, 60 cases in each group. The treatment group was treated with the XIA's No. 1 Sleeping Prescription, while the control group was given estazolam (1 mg) for 6 weeks. The Athens Insomnia Scale (AIS) was used to evaluate the clinical therapeutic effects, while the treatment emergent symptom scale (TESS) was used to evaluate adverse reactions. RESULTS: The total effective rate of the treatment group (80%) was higher than that of the control group (70%), but with no significant difference (P > 0.05). The effective rate for long-term insomnia was 77.8% in the treatment group and 52.4% in the control group, with a significant difference between the two groups (P < 0.05). The adverse reactions shown in the treatment group were obviously fewer and milder than those in the control group. CONCLUSION: The XIA's No. 1 Sleeping Prescription is effective for insomnia of the deficiency type and with no obvious toxic side effects.
